7,215 Shares in Novartis AG (NYSE:NVS) Bought by Agate Pass Investment Management LLC

Agate Pass Investment Management LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 7,215 shares of the company’s stock, valued at approximately $702,000.

Other large investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its holdings in shares of Novartis by 23.1% during the second quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock worth $788,626,000 after purchasing an additional 1,389,610 shares during the period. Fisher Asset Management LLC raised its position in Novartis by 15.7% during the 3rd quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock valued at $196,225,000 after purchasing an additional 231,851 shares during the last quarter. FMR LLC lifted its holdings in Novartis by 5.5% in the 3rd quarter. FMR LLC now owns 1,353,412 shares of the company’s stock worth $155,669,000 after buying an additional 70,314 shares during the period. Natixis Advisors LLC grew its position in shares of Novartis by 2.9% in the 3rd quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock worth $107,986,000 after buying an additional 26,317 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Novartis by 18.7% during the third quarter. Bank of Montreal Can now owns 780,980 shares of the company’s stock valued at $90,289,000 after buying an additional 123,077 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Down 0.4 %

NYSE:NVS traded down $0.38 on Monday, reaching $98.70. 783,379 shares of the stock traded hands, compared to its average volume of 1,315,073. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $201.74 billion, a price-to-earnings ratio of 11.46, a PEG ratio of 1.49 and a beta of 0.57. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The company’s fifty day simple moving average is $101.55 and its 200 day simple moving average is $109.29.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The company had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period in the previous year, the business earned $1.74 EPS. Equities analysts predict that Novartis AG will post 7.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVS has been the topic of several recent analyst reports. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. BMO Capital Markets boosted their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Finally, HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $121.50.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.